myFINACEA.com - About FINACEA - What You Can Expect When Using FINACEA

A quick, convenient routine to help you take control of managing the bumps, pimples and associated redness of your mild to moderate rosacea.

Learn more

About FINACEA - What You Can Expect When Using FINACEA

Studies show that patients using FINACEA experience a reduction in the bumps and pimples, as well as the redness, associated with mild to moderate inflammatory rosacea. Check out the results that some patients with mild to moderate rosacea experienced with FINACEA.

Results shown are for individual patients. Not all patients may have the same results.

Use FINACEA as prescribed

The best results with most therapies take time and patience. This is especially true in the treatment of rosacea, which is a chronic condition. To get the most out of your treatment with FINACEA, it's extremely important to keep applying it regularly as directed by your dermatologist to meet your particular skin care needs, even though you don't "see it working" right away. And once you do see improvement, it's important to keep using FINACEA as directed.

For best results—remember refills

If you've used up your entire prescription of FINACEA and if your face is looking good, you may be tempted to stop using FINACEA. But it's important to keep using FINACEA every day as long as your dermatologist directs, to help maintain results.

INDICATIONS & USAGE

FINACEA is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema, which was present in patients with papules and pustules of rosacea, occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

IMPORTANT SAFETY INFORMATION

FINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.

Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.

Please see full prescribing information for FINACEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.